About this trial
The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.
Eligibility criteria
Qualifiers
Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis
Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee
Will be able to attend and perform physical therapy
Disqualifiers
Received injection therapy for knee osteoarthritis in the past 6 months
Have severe arthritis diagnosed in ≥1 major joint by radiology criteria
History of septic arthritis
Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery)
Trial design
Treatments tested in this trial
- Platelet Rich Plasma
- Emcyte PurePRP Supraphysiologic Concentrating System
- APEX Biologix XCELL PRP System